AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Jan 5, 2021
35290_dirs_2021-01-05_7158a10a-a428-41a3-afe1-413679c80308.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2020-12-31
Reporting Person: Harsch Mutya (Chief Legal Officer and GC)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Common Stock | F | 1822 | $1.58 | Disposed | 325703 | Direct |
Footnotes
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.